GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients
Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 diabetes patients, especially compared to insulin. The study also highlights GLP-1RAs’ potential…